[ad_1]
Peeling Pores and skin Syndrome is a uncommon autosomal illness with no accepted remedy or remedy
Preliminary medical web site and pediatric affected person recognized in New Zealand
Firm actively evaluating opening extra medical websites in different international locations
ASHBURN, Va., Aug. 06, 2024 (GLOBE NEWSWIRE) — Quoin Prescription drugs Ltd. (NASDAQ: QNRX) (the Firm or Quoin) a medical stage, specialty pharmaceutical firm centered on growing and commercializing novel therapies for uncommon and orphan illnesses, as we speak introduced the deliberate initiation of an investigator-led medical research in New Zealand to guage the protection and efficacy of QRX003 in a pediatric affected person with Peeling Pores and skin Syndrome (PSS). QRX003 is Quoin’s most superior pipeline product and is at present being evaluated in two late stage medical trials in the USA as a possible remedy for Netherton Syndrome (NS). Each research are being performed underneath an open Investigational New Drug (IND) software with the Meals and Drug Administration (FDA).
We’re excited to broaden QRX003’s growth into this second indication, peeling pores and skin syndrome, the place it’s believed the mechanism of motion of our product might additionally present a profit for this devastating illness. Given the overlapping nature of how PSS presents, sufferers with the illness are recognized to have been beforehand misdiagnosed as having NS. At the moment there are not any medical research listed for peeling pores and skin syndrome on clinicaltrials.gov as actively recruiting and dosing topics and there’s no accepted remedy or remedy, presenting an additional alternative for Quoin to attain the primary regulatory approval for an additional uncommon genetic illness, said Michael Myers, CEO, Quoin Prescription drugs. The deliberate initiation of this research represents the execution of a key pillar of Quoin’s technique to broaden the medical testing of QRX003 into different uncommon and orphan illness indications and we’re actively assessing extra alternatives past this one.
QRX003 is a novel complete physique, complete life topical lotion that targets the vicious circle of pores and skin irritation and barrier disruption.
Quoin is conducting two ongoing medical trials evaluating QRX003 for the remedy of Netherton Syndrome. For extra details about the trials, please go to: https://www.nethertonsyndromeclinicaltrials.com/.
About Peeling Pores and skin Syndrome (PSS)
Generalized inflammatory peeling pores and skin syndrome (PSS) is a uncommon autosomal recessive genodermatosis attributable to loss-of-function disease-causing variants of the corneodesmosin gene (CDSN), leading to extreme shedding of the superficial layers of the dermis. Sufferers usually undergo from a wide range of circumstances together with extreme ache and power pruritis (itch). There’s at present no accepted remedy for PSS, and sufferers handle signs utilizing over-the-counter emollients.
About QRX003
QRX003 is a topical lotion, formulated with a proprietary supply know-how, and incorporates a broad- spectrum serine protease inhibitor, whose mechanism of motion is meant to carry out the perform of a particular protein, referred to as LEKTI. The absence of LEKTI in Netherton sufferers results in extreme pores and skin shedding leading to a extremely porous and compromised pores and skin barrier. QRX003 is designed to result in a extra normalized pores and skin shedding course of and the formation of a stronger and more practical pores and skin barrier.
About Quoin Prescription drugs Ltd.
Quoin Prescription drugs Ltd. is an rising specialty pharmaceutical firm centered on growing and commercializing therapeutic merchandise that deal with uncommon and orphan illnesses. We’re dedicated to addressing unmet medical wants for sufferers, their households, communities and care groups. Quoin’s modern pipeline contains three merchandise in growth that collectively have the potential to focus on a broad variety of uncommon and orphan indications, together with Netherton Syndrome, Peeling Pores and skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. For extra info, go to: www.quoinpharma.com.
Cautionary Word Concerning Ahead Trying Statements
The Firm cautions that statements on this press launch that aren’t an outline of historic details are forward-looking statements inside the which means of the Personal Securities Litigation Reform Act of 1995. Ahead-looking statements could also be recognized by means of phrases referencing future occasions or circumstances resembling count on, intend, plan, anticipate, consider, and can, amongst others. All statements that mirror the Firm’s expectations, assumptions, projections, beliefs, or opinions in regards to the future, apart from statements of historic reality, are forward-looking statements, together with, with out limitation, statements regarding the Firm’s anticipated money runway, the assumption that the information set from each medical research might probably be sufficiently sturdy and complete to help an NDA submitting, with out the necessity for any extra medical research in Netherton topics, and the assumption that sure protocol modifications has enhanced the potential for a profitable end result and Quoin’s merchandise in growth collectively have the potential to focus on a broad variety of uncommon and orphan indications, together with Netherton Syndrome, Peeling Pores and skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. As a result of such statements are topic to dangers and uncertainties, precise outcomes might differ materially from these expressed or implied by such forward-looking statements. These forward-looking statements are primarily based upon the Firm’s present expectations and contain assumptions that will by no means materialize or might show to be incorrect. Precise outcomes and the timing of occasions might differ materially from these anticipated in such forward-looking statements on account of varied dangers and uncertainties together with, however not restricted to, the Firm might have to boost extra funds earlier than deliberate, the medical research might not generate knowledge which is sufficiently sturdy and complete to help an NDA submitting and the Firm’s potential to acquire regulatory approvals. Extra detailed details about the dangers and uncertainties affecting the Firm is summarized within the Firm’s Annual Report on Type 10-Okay for the 12 months ended December 31, 2023 and in different filings the Firm has made and will make with the SEC sooner or later. One shouldn’t place undue reliance on these forward-looking statements, which converse solely as of the date on which they have been made. The Firm undertakes no obligation to replace such statements to mirror occasions that happen or circumstances that exist after the date on which they have been made, besides as could also be required by legislation.
For additional info, contact:
Quoin Prescription drugs Ltd.Michael Myers, Ph.D., CEOmmyers@quoinpharma.com
Investor RelationsPCG AdvisoryJeff Ramsonjramson@pcgadvisory.com(646) 863-6341
Supply: Quoin Prescription drugs, Inc.
[ad_2]
Source link
